Coeptis Therapeutics Stock to Reverse Split on Tuesday, December 31st (NASDAQ:COEP)

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPFree Report) shares are scheduled to reverse split on Tuesday, December 31st. The 1-20 reverse split was announced on Friday, December 27th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 30th.

Coeptis Therapeutics Stock Down 13.6 %

Shares of Coeptis Therapeutics stock traded down $0.03 during trading on Friday, hitting $0.18. 15,789,481 shares of the stock traded hands, compared to its average volume of 1,243,014. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.03. The stock’s fifty day simple moving average is $0.19 and its 200 day simple moving average is $0.22. The firm has a market cap of $7.49 million, a P/E ratio of -0.63 and a beta of -0.90. Coeptis Therapeutics has a 52-week low of $0.13 and a 52-week high of $0.82.

About Coeptis Therapeutics

(Get Free Report)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

See Also

Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.